DBV Technologies(US:DBVT) Newsfilter·2024-07-29 05:30Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [4] - The company is headquartered in Châtillon, France, with North American operations in Warren, NJ [2] - DBV's ordinary shares are traded on Euronext Paris and its American Depositary Shares (ADSs) are traded on the Nasdaq Global Select Market [2] Technology and Products - DBV Technologies is investigating the use of its proprietary technology platform, Viaskin, to address food allergies through epicutaneous immunotherapy (EPIT™) [4] - The Viaskin platform aims to introduce microgram amounts of biologically active compounds to the immune system via intact skin, seeking to modify the underlying allergy by re-educating the immune system [4] - The company is currently conducting clinical trials for Viaskin Peanut in peanut allergic toddlers and children [4] Upcoming Events - DBV Technologies will host a conference call and live audio webcast on July 30, 2024, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update [1][7] - A live webcast of the call will be available on the company's website, with a replay accessible after the event [6]